Pivotal Therapeutics Inc. announced that it has entered into a memorandum of understanding with Korea Animal Medical Science Institute and its newly created affiliate for the exclusive sales and distribution of the BeneFishial family of products. The BeneFishial family of products consists of the following six products: (i) BeneFishial for overall health and well being, (ii) BeneFishial for cardiovascular health, (iii) BeneFishial for prenatal health, (iv) BeneFishial for toddler's health, (v) BeneFishial for child's health and (vi) BeneFishial for pet's health (veterinary application). The distribution agreement focuses on Pivotal's BeneFishial line of products for the nutraceutical and veterinary markets in Korea and the veterinary market in Japan.

The agreement also provides for an upfront payment and guaranteed minimum annual sales targets to be achieved.